Endometrial Cancer Market Size, Share & Industry Analysis, By Drug Class (PD-1 Inhibitors, Platinum Compounds, Taxanes, VEGFR/Multikinase Inhibitors, Progestins, and Others), By Cancer Type (Endometrioid Adenocarcinoma, Serous Endometrial Carcinoma, Clear Cell Carcinoma, and Others), By Age Group (Pediatric and Adults), By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Others) and Regional Forecast, 2026-2034

Last Updated: June 16, 2026 | Format: PDF | Report ID: FBI117372

Buy Now

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 12.84% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Region
By Drug Class	PD-1 Inhibitors Platinum Compounds Taxanes VEGFR/Multikinase Inhibitors Progestins PD-L1 Inhibitors Others
By Cancer Type	Endometrioid Adenocarcinoma Serous Endometrial Carcinoma Clear Cell Carcinoma Carcinosarcoma Others
By Age Group	Pediatric Adults
By Therapy	Chemotherapy Immunotherapy Targeted Therapy Hormonal Therapy Others
By Route of Administration	Oral Parenteral
By Distribution Channel	Hospital Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies Specialty Pharmacies
By Region	North America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country) U.S. Canada Europe (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa